N
TVTX icon

Natixis’s Travere Therapeutics TVTX Stock Holding History

Natixis’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,212
Closed -$76.8K – 1310
2025
Q3 		$76.8K Buy
+3,212
New +$60.4K ﹤0.01% 914
2023
Q4 		– Sell
-163,500
Closed -$1.46M – 1174
2023
Q3 		$1.46M Buy
163,500
+28,500
+21% +$402K 0.01% 450
2023
Q2 		$2.07M Buy
135,000
+94,700
+235% +$1.72M 0.02% 420
2023
Q1 		$906K Sell
40,300
-874
-2% -$18.6K 0.01% 541
2022
Q4 		$866K Sell
41,174
-58,826
-59% -$1.25M ﹤0.01% 658
2022
Q3 		$2.56M Buy
+100,000
New +$2.58M 0.01% 543
2022
Q2 		– Sell
-65,392
Closed -$1.69M – 1366
2022
Q1 		$1.69M Buy
+65,392
New +$1.74M 0.01% 789

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Natixis's TVTX Position: Q4 2025 in Review

Natixis sold out of Travere Therapeutics (TVTX) in Q4 2025, closing a stake of 3,212 shares — an estimated $76.8K sold.

Natixis first reported a position in TVTX in Q1 2022 and held it in 7 quarters. The position peaked at $2.56M in Q3 2022. 278 funds tracked by Wall St. Rank hold TVTX as of Q4 2025.

  • Natixis reported no remaining Travere Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Natixis sold 3,212 Travere Therapeutics shares in Q4 2025, an estimated $76.8K.
  • Natixis first reported a position in Travere Therapeutics in Q1 2022 and held it in 7 quarters.
  • Natixis's Travere Therapeutics position peaked at $2.56M in Q3 2022.
  • 278 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2025.

Based on Natixis's 13F filing for Q4 2025, filed 13 Feb 2026.